Ticker Launch
Sign inTry it free

SPAC · Merger completed

FS Development Corp. II

Business combination with Pardes Biosciences, Inc.

FS Development Corp. II is a blank-check company (SPAC) that raised $25M in its initial public offering on Feb 18, 2021, listing on Nasdaq Capital Market. It completed its business combination with Pardes Biosciences, Inc. on Dec 23, 2021; the combined company is Pardes Biosciences, Inc. (PRDS). Declaration Partners led the IPO, with J.P. Morgan and Genesis Merchant. White & Case advised the SPAC and Skadden, Arps advised the underwriters on the IPO.

Pardes Biosciences is a biopharmaceutical company whose lead product candidate, PBI-0451, is being developed as an oral direct-acting antiviral drug to treat and prevent SARS-CoV-2 infections. It is the target of a business combination with a Foresite Capital blank check company.

Status
Merger completed
IPO date
Feb 18, 2021
IPO size
$25M
IPO exchange
Nasdaq Capital Market
Target
Pardes Biosciences, Inc.
Announced
Jun 29, 2021
Closed
Dec 23, 2021
Combined company
Pardes Biosciences, Inc. (PRDS)
IPO underwriters
Declaration Partners, J.P. Morgan, Genesis Merchant, Genentech, Mereo BioPharma and Foresite Capital
SPAC counsel (IPO)
White & Case
Underwriters' counsel (IPO)
Skadden, Arps

More on this SPAC for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Try it free for 7 daysOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other deSPACs that closed in 2021